

Small Fiber Neuropathy and Sarcoidosis

Jinny Tavee, M.D.
Assistant Professor
Neuromuscular Center
Cleveland Clinic Foundation
October 6, 2012

Neurosarcoidosis

- Seen in 5-15% of patients with sarcoidosis
- Affects any portion of the CNS or PNS
 - -Cranial neuropathies
 - -Brain parenchyma
 - -Meningeal disease
 - -Peripheral neuropathy
- Disorder of small somatic and/or autonomic fibers which results in sensory paresthesias or autonomic dysfunction

Small Fiber Neuropathy

- Under-recognized and more common than previously thought
- Prevalence unknown
 - 44% (31/70) of severe sarcoidosis patients reported peripheral pain/paresthesias or symptoms of autonomic dysfunction
 - None with DM
 - Skin biopsy in 7 of 7 patients showed reduced IENFD

Hoitsma et al. Lancet 2002;359:2085-6

Anatomy: Small nerve fibers

- Thinly myelinated A-delta fibers and unmyelinated C-fibers
- Innervate skin and involuntary muscles (cardiac, smooth muscles)
- •Clinical:




- Autonomic: dry eyes, dry mouth, orthostasis, diarrhea/constipation, sweating changes, sexual dysfunction
- Length vs non-length dependent






Anatomy: small fibers



Tavee J, Zhou L. Cleve Clin J Med 2009; 76:297-305.

Pathophysiology

- Axon loss
- Cytokines and immune factors
 - Increased gene expression of local and systemic cytokines
 - Responsive to anti-TNFα agents
- Oxidative stress



Diagnostic Evaluation


- Examination typically normal
 - May have mild sensory loss including vibration
- Nerve conduction studies and EMG normal
 - Evaluate large fibers
- Specialized testing:
 - -Skin biopsy
 - Quantitative sudomotor axon reflex testing (QSART)
 - Cardiovagal/adrenergic autonomic testing: tilt table,
 Valsalva ratio, heart rate variability to deep breathing
 - -Thermoregulatory sweat testing
- Exclusion of other etiologies: diabetes, B12, thyroid




Skin Biopsy

- Minimally invasive
- 3mm diameter punch biopsy ankle, distal thigh, proximal thigh
- Immunostained with PGP 9.5 panaxonal marker
- Reduced Intraepithelial nerve fiber density (IEFD)
- 88% sensitive

Skin Biopsy




Normal skin biopsy



Tavee J, Zhou L. Cleve Clin J Med 2009; 76:297–305.



Small fiber neuropathy biopsy



Tavee J, Zhou L. Cleve Clin J Med 2009; 76:297–305.




Quantitative Sudomotor Axon Reflex Test (QSART)

- Measures sweat output in response to acetylcholine iontophoresis
- Reflects function of postganglionic sympathetic unmyelinated sudomotor fibers
- Output and latency compared to normative values
- Left forearm, proximal leg, distal leg and foot
- Current is 2 mA for 5 minutes
- 72% sensitivity



QSART



Treatment Options

- Immune-modulating therapy
- Pain management
- Supportive care

Immune-modulating therapy

- Intravenous Immune globulin
 - -400mg/kg/D IV for 5 days
 - -Repeat monthly at least for 3 months
 - -Adjust dose as needed and taper when possible
 - -Helpful for SFN with somatic and autonomic involvement
- TNF-α blockers
- Corticosteroids
- Erythropoetin
 - -Neuroprotective in animal models of neuropathy
 - -TNF-α antagonist
 - -ARA 290 avoids hematopoetic/thrombotic effects



Pain Management

- Medications
- Spinal cord stimulation
- Intrathecal pain pump

First line: Antidepressants

Antidepressants	Dosages (per day)	Common side effects
Amitryptiline	20-150 mg	Sedation, weight gain, anticholinergic effects, sexual dysfunction (side effects most prominent in amitryptiline)
Nortryptiline	20-150 mg	
Desipramine	20-200 mg	
Duloxetine	60-120 mg	
Venlafaxine	75-225 mg	Anxiety, insomnia, weight loss anticholinergic effects, sexual
		dysfunction, arrhythmia

Anticonvulsants	Dosages (per day)	Common side effects
Gabapentin	300-3600 mg	Sedation, dizziness, peripheral edema, weight gain
Pregabalin	150-300 mg	Similar to gabapentin, but worse
Topiramate	25-400 mg	Weight loss, sedation, cognitive slowing, renal stones, paresthesias
Zonegran	100-600mg	Weight loss, sedation, cognitive slowing, renal stones
Levetiracetam	500-3000mg	Dizziness, sedation, irritability



Non-opioids: Topical agents

Topical anesthetics	Dosages (per day)	Common side effects
Lidocaine 5% patch	3 patches for 12 hrs	Local edema, burning, erythema
Capsaicin cream	0.02525% TID-QID	Burning, worse with heat exposure
Capsaicin 8% patch	Apply 60-90 minutes	Burning, worse with heat exposure



Acetyl L Carnitine

Chemotherapy PN

- Oral 1gm TID for 8 weeks in 25 patients with PN due to paclitaxel or cisplatin
- Improved sensory neuropathy symptoms in 60% pts

Antiretroviral PN:

- ■Oral 2gm/D for 4 weeks in 20 HIV+ pts
- Mean pain intensity score was significantly reduced

Diabetes PN:

- Oral 500 and 1000 mg TID for 6 and 12 months in 1335 patients with diabetic PN
- •27% with pain, all significantly improved in 1000mg TID group



Natural supplements

- Alpha-lipoic acid
 - Natural cofactor of dehydrogenase complex
 - —IV 600mg/D in patients with DM distal sensory and autonomic neuropathy -14 treatments
 - Oral dose and length of treatment not well established
- Vicks vaporub
- Horse liniment cream
- Juiceplus® (or Costco equivalent: Juice festiv®)

Supportive treatment

- Nutrition: Food as medicine
- Gluten-free diet
- Avoid/reduce EtOH intake
- Exercise, exercise, exercise
 - —Aqua therapy
 - -Recumbent bike
- Mind body therapies: tai chi, qigong, meditation, yoga, pilates
- Massage
- Transcutaneous electrical stimulation



Prognosis

- Ambulation and strength are preserved
- Pain can last months to years if untreated
- Markedly affects quality of life
- Remitting and relapsing
- Slow progression



